McKeating Cara, Cadden Ian, McDougall Neil, Jessop Lucy, Quah Say, Lavelle Michael, Griffths Alison, McCaughey Conall
Regional Virus Laboratory, Royal Victoria Hospital, Belfast HSC Trust, Belfast BT12 6BA.
Liver Unit, Royal Victoria Hospital, Belfast HSC Trust, Belfast BT12 6BA.
Ulster Med J. 2018 Oct;87(3):177-180. Epub 2018 Oct 1.
The rate of progression of acute Hepatitis B (HBV) to chronic disease is quoted as <10%. The purpose of this study was to determine the rate of progression from acute to chronic HBV in Northern Ireland (NI), assessing the influence of age, gender and biochemical parameters.
All "acute" HBV cases diagnosed in NI between 2011 and 2015 were reviewed. Inclusion criteria: 1). positive HBsAg and positive HBV core IgM; 2). in the absence of positive HBV core IgM, positive HBsAg with a recent negative HBsAg. Patient age, HBsAg, HBV core IgM, peak bilirubin and peak ALT were recorded, along with date and result of repeat HbsAg testing. Mann-Whitney U test was used to compare mean age, peak ALT and bilirubin between clearing and non-clearing groups. Fisher's exact test was used to compare progression to chronicity according to gender and age less than or greater than 50yrs.
Of 80 identified cases, 4 incorrectly categorised cases were excluded. Of the remaining 76, (15 female (mean age 37.27yr), 61 male (mean age 47.39yr)) follow-up data was available for 71 patients (15 female (mean age 37.27yr), 56 male (48.59yr)). All female patients cleared HBV. 42 of 61 males cleared HBV (p=0.0313).Overall the chronicity rate was 18.42% The mean age of those clearing the virus was 43.88 years, versus 55.64 years for those going on to develop chronic HBV (Mann-Whitney U test, z= -2.68, p=0.0037). Clearance rate was 83.72% in patients aged <50yrs and 63.64% in patients 50yrs (p=0.0068).Mean peak ALT (U/L) and peak bilirubin (mol/L) for the clearing group were 2130 and 174 respectively compared to 656 and 100 for the non-clearing group (z= -3.51, p=0.0002, z= -2.35, p=0.009).
Our results suggest a higher than expected rate of progression from acute to chronic HBV with a significantly higher risk for those over 50yrs. This suggests a need to revise information provided to older patients with acute HBV regarding the likelihood of progression.
急性乙型肝炎(HBV)进展为慢性疾病的比率据报<10%。本研究的目的是确定北爱尔兰(NI)急性HBV向慢性HBV的进展率,评估年龄、性别和生化参数的影响。
回顾了2011年至2015年在NI诊断的所有“急性”HBV病例。纳入标准:1)HBsAg阳性且HBV核心IgM阳性;2)在无HBV核心IgM阳性的情况下,HBsAg阳性且近期HBsAg阴性。记录患者年龄、HBsAg、HBV核心IgM、胆红素峰值和ALT峰值,以及重复HBsAg检测的日期和结果。采用曼-惠特尼U检验比较清除组和未清除组的平均年龄、ALT峰值和胆红素峰值。采用Fisher精确检验比较按性别和年龄小于或大于50岁划分的慢性化进展情况。
在80例确诊病例中,排除4例分类错误的病例。在其余76例中(15例女性(平均年龄37.27岁),61例男性(平均年龄47.39岁)),71例患者(15例女性(平均年龄37.27岁),56例男性(48.59岁))有随访数据。所有女性患者均清除了HBV。61例男性中有42例清除了HBV(p=0.0313)。总体慢性化率为18.42%。清除病毒者的平均年龄为43.88岁,而进展为慢性HBV者的平均年龄为55.64岁(曼-惠特尼U检验,z=-2.68,p=0.0037)。<50岁患者的清除率为83.72%,50岁及以上患者的清除率为63.64%(p=0.0068)。清除组的平均ALT峰值(U/L)和胆红素峰值(μmol/L)分别为2130和174,而未清除组分别为656和100(z=-3.51,p=0.0002,z=-2.35,p=0.009)。
我们的结果表明,急性HBV向慢性HBV的进展率高于预期,50岁以上患者风险显著更高。这表明需要修订向急性HBV老年患者提供的关于进展可能性的信息。